It would be nice to drill down more on Vap issues. there's plenty of questions to be sure.
Back in February PC told me they wouldn't be pursuing Vap for this indication if there wasn't any industry interest. Now RP says people arnt prepared to pay for a pill that reduces asthma exacerbations?
I would love to know who's telling RP the viral meningitis market is economic? Who's interested enough to fund the trials?
What about other non rhinovirus markets? I know the Bill Gates Foundation is prepared to fund a polio antiviral but again is that enough to make Vap economic in this niche EV market?
We've sunk 10 years and $30m into this program and they still dont know whether they are coming or going...
BTA Price at posting:
0.0¢ Sentiment: None Disclosure: Held
